Evonik, Coopmed agree on wound dressing distro deal

Evonik announced today that it signed an agreement for medical technology company Coopmed to distribute the epicite wound dressing.

Jena, Germany-based Evonik said Coopmed will distribute the epicite dressing made from biosynthetic cellulose exclusively to the German market for chronic wound care. Epicite represents part of the portfolio from JeNaCell, which Evonik acquired in 2021.

“We are excited to work with a highly experienced partner like Coopmed for the market development and distribution of epicite® to advance the treatment of chronic wounds,” said Dana Kralisch, GM of JeNaCell. “Together, we will work to make epicite® available to outpatients throughout Germany. We would like to thank all wound experts and professional users who supported us with case studies, practical advice and their personal experiences using the product.”

JeNaCell is designed to produce biosynthetic cellulose. The nature-identical material is suitable for wound cleansing an…

Read more
  • 0

Evonik acquires JeNaCell and its nanostructured biomaterial

Evonik (Essen, Germany) recently announced that has purchased JeNaCell and its nanostructured biomaterial for wound dressings and dermatology.

The financial terms of the deal were not disclosed.

JeNaCell (Jena, Germany) provides biotechnologically derived cellulose. Evonik first invested in the startup in 2015.

“JeNaCell has developed one of the most innovative biomaterials for medical device technologies. With the help of the creativity and expertise of JeNaCell’s specialists, we will ensure that even more patients benefit from these products in the future,” said Thomas Riermeier, head of Evonik’s Health Care business line, said in an Aug. 2 news release. “The acquisition will help us to further strengthen our position as an innovation hub for the world’s leading medical technology companies.”


Read more
  • 0